Download MendeleyIdentification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Fujimoto, J., Kurasawa, O., Takagi, T., Liu, X., Banno, H., Kojima, T., Asano, Y., Nakamura, A., Nambu, T., Hata, A., Ishii, T., Sameshima, T., Debori, Y., Miyamoto, M., Klein, M.G., Tjhen, R., Sang, B.C., Levin, I., Lane, S.W., Snell, G.P., Li, K., Kefala, G., Hoffman, I.D., Ding, S.C., Cary, D.R., Mizojiri, R.(2019) ACS Med Chem Lett 10: 1498-1503
- PubMed: 31620240
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00400
- Primary Citation of Related Structures:
6N3L, 6N3N, 6N3O - PubMed Abstract:
General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibitors as first-in-class antitumor agents and conducted modification of the substructure of sulfonamide derivatives with expected type I half binding on GCN2. Our synthetic strategy mainly corresponding to the αC-helix allosteric pocket of GCN2 led to significant enhancement in potency and a good pharmacokinetic profile in mice. In addition, compound 6d , which showed slow dissociation in binding on GCN2, demonstrated antiproliferative activity in combination with the asparagine-depleting agent asparaginase in an acute lymphoblastic leukemia (ALL) cell line, and it also displayed suppression of GCN2 pathway activation with asparaginase treatment in the ALL cell line and mouse xenograft model.
Organizational Affiliation:
Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
